This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
May 7-10, 2023 | In-Person + Digital
San Diego, CA, USAManchester Grand Hyatt San Diego

Reshma Shringarpure, PhD
VP, Clinical Research and Medical Affairs at Akero Therapeutics


Reshma Shringarpure is Vice President of Clinical Research and Medical Affairs at Akero Therapeutics. She brings over 15 years of experience in clinical and medical affairs across multiple therapeutic areas including GI, non-viral liver disease, and metabolic disease. Reshma joins Akero from Intercept Pharmaceuticals, where she was the clinical lead for Intercept’s late-stage NASH program and was integral to achieving several company milestones towards registrational filings in US and Europe. Prior to joining Intercept, she was the director of medical affairs at Santarus, subsequently acquired by Salix Pharmaceuticals. Leading up to this role, Reshma held several scientific positions at Prometheus Therapeutics and Diagnostics as the clinical and medical affairs lead focused on Prometheus’ GI portfolio (IBS, IBD and celiac disease). She started her pharmaceutical career at Amylin Pharmaceuticals focusing on metabolic diseases and is a co-author of several peer-reviewed publications.

Reshma earned her PhD in molecular biology from the University of Southern California and completed her post-doctoral training at Dana Farber Cancer Institute, Harvard Medical School.

Agenda Sessions

  • Salient Features and Clinical Development of FGF21 Analog Efruxifermin in NASH